A Soluble Epoxide Hydrolase Inhibitor Upregulated KCNJ12 and KCNIP2 by Downregulating MicroRNA-29 in a Mouse Model of Myocardial Infarction

Xiao-Jun Zhang,1* Cai-Xiu Liao,1* Kai-Jun Sun,1 Lei-Ling Liu,1 Dan-Yan Xu1

1Department of Internal Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha; 2Department of Geratology, The Third Hospital of Changsha, Changsha, Hunan, China

ABSTRACT

Background: Soluble epoxide hydrolase inhibitors (sEHi) have anti-arrhythmic effects, and we previously found that the novel sEHi t-AUCB (trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxyl]-benzoic acid) significantly inhibited ventricular arrhythmias after myocardial infarction (MI). However, the mechanism is unknown. It’s known that microRNA-29 (miR-29) participates in the occurrence of arrhythmias. In this study, we investigated whether sEHi t-AUCB was protective against ischemic arrhythmias by modulating miR-29 and its target genes KCNJ12 and KCNIP2.

Methods: Male 8-week-old C57BL/6 mice were divided into five groups and fed distilled water only or distilled water with t-AUCB of different dosages for seven days. Then, the mice underwent MI or sham surgery. The ischemic region of the myocardium was obtained 24 hours after MI to detect miR-29, KCNJ12, and KCNIP2 mRNA expression levels via real-time PCR and KCNJ12 and KCNIP2 protein expression levels via western blotting.

Results: MiR-29 expression levels were significantly increased in the ischemic region of MI mouse hearts and the mRNA and protein expression levels of its target genes KCNJ12 and KCNIP2 were significantly decreased. T-AUCB prevented these changes dose-dependently.

Conclusion: The sEHi t-AUCB regulates the expression levels of miR-29 and its target genes KCNJ12 and KCNIP2, suggesting a possible mechanism for its potential therapeutic application in ischemic arrhythmia.

INTRODUCTION

Ischemic arrhythmias, especially the ventricular arrhythmias, are the main reasons for sudden death in acute myocardial infarction (MI). As conventional treatment relies on the classic anti-arrhythmic drugs with proarrhythmic potential and limited effectiveness, it is crucial to discover more effective anti-arrhythmic drugs.

Epoxyeicosatrienoic acids (EETs) are the main metabolites of arachidonic acids catalyzed by cytochrome P450 (CYP450) epoxygenase system [Spector 2009]. A potent cardioprotective role for EETs has been established in the past decade, which was explained by antihypertensive and antiby hypertrophic effects in the cardiovascular system [He 2016; Červenka 2018; Yeboah 2016]. However, EETs are unstable and quickly degrade into inactive dihdroxyicosatrienoic acids (DHETs) in the presence of soluble epoxide hydrolase (sEHi) [Inceoglu 2007]. Soluble epoxide hydrolase inhibitors (sEHi) could enhance the beneficial effects of EETs by elevating endogenous EET levels [Xu 2013; Guo 2018]. Importantly, increasing studies have found that sEHi could prevent and reduce the occurrence of arrhythmias both in murine models with hypertrophy and MI and serve as a promising drug for anti-arrhythmia [Červenka 2018; Gui 2018; Liu 2017; Gui 2017; Sirish 2016]. However, the underlying mechanism is unknown.

Previously, we found that the sEHi suppressed the susceptibility to increased ventricular arrhythmias after MI through the modulation of microRNA-1 (miR-1) and its target genes, which encode various ion channel proteins associated with arrhythmias [Liu 2017]. In preliminary study, higher microRNA-29 (miR-29) expression levels were tested in the ischemic area post-MI through miRNA microarray technology. Meanwhile, via miRBase and miRanda target prediction program, it has been predicted that the target genes of miR-29 included KCNJ12 (potassium channel inwardly rectifying subfamily J member 12) and KCNIP2 (voltage-gated potassium channel–interacting protein 2), which both encode important potassium channel–related proteins involved in arrhythmia. As miR-1 and miR-29 have the same proarrhythmic effects in the heart [Dawson 2013; Boštjančič 2014; Zhao 2016], the present research aimed to investigate whether sEHi trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxyl]-benzoic acid (t-AUCB) could inhibit ischemic arrhythmias by modulating miR-29 and its target genes KCNJ12 and KCNIP2.

METHODS

Mice and MI Model

All animal protocols were approved by the Animal Research Committee, Central South University, Hunan,
Male 8-week-old C57BL/6 mice (26.07 ± 0.55 g) were obtained from the Medical Experimental Animal Center of Hunan Province. The mice were randomly divided into five groups (n = 6): (i) Sham, (ii) MI, (iii) 0.001 mg/L t-AUCB + MI, (iv) 0.01 mg/L t-AUCB + MI, (v) 0.1 mg/L t-AUCB + MI. t-AUCB (0.01, 0.1, and 1 mg/L) was administered to mice orally in drinking water for 7 days prior to surgery. The mice were anesthetized with 1.5% isoflurane inhalation; the trachea was intubated and the mice were ventilated with a small respirator (MiniVent Type 845, Hugo Sachs Elektronik, March, Germany). The left anterior descending coronary artery was ligated via left thoracotomy between the third and fourth ribs, as described previously [Ulu 2008]. Sham-operated animals underwent the same procedure without occlusion of the coronary artery.

**Materials**

The t-AUCB was a gift from Prof. Bruce D. Hammock (University of California, Davis, CA, USA). Rabbit anti-mouse KCNJ12 and β-actin antibodies were purchased from Abcam (Cambridge, UK) and rabbit anti-mouse KCNJ12 (or Kir2.2) was purchased from GeneTex (Irvine, CA, USA). TaqMan MicroRNA RT Kit, TaqMan MicroRNA-29b assays, TaqMan U6 snRNA assay, and TaqMan Universal PCR Master Mix were purchased from Applied Biosystems (NY, USA).

**Tissue Samples**

Mice were killed by cervical dislocation under anaesthesia with 1.5% isoflurane 24 h after MI and the hearts were obtained. Ventricular tissues from the border zone of the infarcted region were dissected and sliced into 2-mm thick sections. Samples were stored at -80°C.

**Histological Analysis**

The hearts were fixed in neutralized formalin buffer for 24–48 h, and then cut transversely from the apex of the myocardium to the base. The fixed samples were dehydrated in an ethanol gradient, paraffin-embedded, and sectioned into 4-μm slices. After deparaffinization, the samples were stained with hematoxylin–eosin (HE) for histological examination.

**Real-Time PCR Detection of miR-29, KCNJ12, and KCNIP2 mRNA**

Total RNA was isolated with TRIzol reagent (Invitrogen) from mouse hearts obtained post-MI. MiR-29 mRNA levels were analyzed by real-time reverse transcription (RT)-PCR using the TaqMan MicroRNA RT Kit (Applied Biosystems). Briefly, 10 ng total RNA was reverse-transcribed with specific stem-loop RT primers using the RT kit according to the manufacturer’s instructions. Real-time RT-PCR was performed on complementary DNA (cDNA) using specific primers designed based on the mouse miR-29 sequence. MiR-29 expression was calculated using the comparative threshold cycle (Ct) method (2^ΔΔCt). Real-time RT-PCR was performed using the following primers:

- **KCNJ12**: 5′-CCTGCGTAAAGTCACATCG-3′ (forward), 5′-GCAAGATGTTGGATGGTGAT-3′ (reverse);
- **KCNIP2**: 5′-GTCTCTTTGGAAGACAGCGT-3′ (forward), 5′-GCAACTCTTCTGCTGTGAAC-3′ (reverse);
- **Gapdh**: 5′-AAGCCCACCATCATTCTCCAGGAG-3′ (forward), 5′-AGCCCCATTCAACTGAAAG-3′ (reverse).

**Western Blotting**

Immunoblotting was performed as previously described [Liu 2013]. The primary antibodies were anti-Kir2.2 (1:1000; GeneTex) and anti-KCNIP2 (1:1000; Abcam); anti-β-actin antibody (1:1000; Abcam) was used as the internal loading control.

**Statistical Analysis**

Data were analyzed using the SPSS 19.0 statistical package. Results are expressed as the mean ± SEM. One-way analysis of variance followed by Bonferroni’s post-hoc test was used for multiple comparisons. All assays were performed in triplicate. P < .05 was considered statistically significant.

**RESULTS**

**Identification of Mouse Model of MI**

The left ventricular apex of the heart below the ligature turned pale and thin 24 h after MI (Figure 1, B). Hearts in the sham group had normal shape and structure (Figure 1, A). There were no degenerated or necrotic cells in the sham group (Figure 1, C). In the MI group, there were large amounts of degenerated and necrotic cells. Myocardial cells in the infarcted zone were stained a homogeneous red, and their nuclei were not visible. The myofiber arrangement was disordered (Figure 1, D).

**Influence of t-AUCB on miR-29 Expression in Ischemic Area of MI Mouse Hearts**

MiR-29 expression was increased by 6.3-fold in the MI group as compared with the sham group (n = 6, all P < .05) (Figure 2). T-AUCB decreased miR-29 expression dose-dependently. Compared with the MI group, miR-29 expression was decreased to 67%, 42%, and 25% in the 0.01 mg/L t-AUCB+MI group, 0.1 mg/L t-AUCB+MI group, and 1 mg/L t-AUCB+MI group, respectively; all differences were statistically significant (n = 6, all P < .05).
Influence of t-AUCB on KCNJ12 and KCNIP2 mRNA Expression in the Ischemic Area Post-MI

KCNJ12 and KCNIP2 mRNA expression was decreased to 27% and 14% in the ischemic myocardium of the MI group (n = 6, all P < .05), respectively, as compared with the sham group (n = 6, all P < .05) (Figure 3). T-AUCB increased KCNJ12 and KCNIP2 mRNA expression dose-dependently. In the 0.01 mg/L t-AUCB+MI, 0.1 mg/L t-AUCB+MI, and 1 mg/L t-AUCB+MI groups, KCNJ12 mRNA expression was 0.96-fold, 1.8-fold, and 2.7-fold, respectively, compared to the MI group. The 0.1 mg/L t-AUCB+MI and 1 mg/L t-AUCB+MI groups were statistically significantly different compared with the MI group (n = 6, all P < .05) (Figure 3, A). Compared with the MI group, KCNIP2 mRNA expression levels were increased by 3-fold, 6.5-fold, and 7.9-fold in the 0.01 mg/L t-AUCB+MI, 0.1 mg/L t-AUCB+MI, and 1 mg/L t-AUCB+MI groups, respectively; the differences were statistically significant (n = 6, all P < .05) (Figure 3, B).

Influence of t-AUCB on KCNJ12 and KCNIP2 Protein in the Ischemic Area Post-MI

Compared with the sham group, KCNJ12 and KCNIP2 protein expression was decreased to 23% and 20%, respectively, in the ischemic myocardium of the MI group (n = 6, all P < .05) (Figure 4). T-AUCB increased KCNJ12 and KCNIP2 protein expression dose-dependently. In the 0.01 mg/L t-AUCB+MI, 0.1 mg/L t-AUCB+MI, and 1 mg/L t-AUCB+MI groups, KCNJ12 protein expression was increased by 1.9-fold, 2.7-fold, and 4.6-fold, respectively, compared to the MI group (Figure 4, A). Compared with the MI group, KCNIP2 protein expression levels were increased by 2.5-fold, 3.6-fold, and 4.6-fold in the 0.01 mg/L t-AUCB+MI, 0.1 mg/L t-AUCB+MI, and 1 mg/L t-AUCB+MI groups, respectively. All differences were statistically significant (n = 6, all P < .05) (Figure 4, B).

DISCUSSION

The present study shows that miR-29 expression levels were significantly increased in the ischemic region of myocardium from the MI group, while KCNJ12 and KCNIP2 mRNA and protein expression levels were significantly decreased. The t-AUCB dose-dependently decreased miR-29 expression levels and increased KCNJ12 and KCNIP2 mRNA and protein expression levels.

We found that miR-29 was increased in the ischemic region after MI. Our findings were consistent with that of Dong, who found that miR-29 was increased by 2.4 times in the ischemic region at 6 h after MI in rats [Dong 2009]. However, van Rooij et al [van Rooij 2008] found that miR-29 was decreased in the ischemic region in MI mice at 3 days and 14 days after MI. Shi et al [Shi 2010] reported that miR-29 was decreased in the ischemic region in MI mice at 3 days and 14 days after MI. Port et al also found that miR-29 was decreased in the ischemic region at 14 days after MI in mice [Port 2011]. The above studies appeared to be the opposite of our findings, revealing miR-29 family was dysregulated in the heart during post-MI remodeling. MiR-29 was predicted to function as inhibitors of numerous mRNAs involved in ECM remodeling.
production and fibrosis [van Rooij 2008; Zhu 2013]. It is possible that the different time of detection in our study led to the differing results. We detected miR-29 expression levels in the ischemic region at 24 h after MI in mice, and Dong detected miR-29 expression levels in the ischemic region at 6 h after MI, the acute phase of MI. By contrast, Rooij et al, Shi et al, and Port et al detected miR-29 expression levels in the ischemic region at 3 days, 7 days, and 14 days after MI, respectively, the proliferative phase (3 days to weeks after MI). In this period, the synthesis of ECM proteins such as collagen and laminin was increased [Talman 2016]. Reduced miR-29 expression was correlated to the appearance of fibrotic ECM, which contributed to adverse ventricular remodeling after MI [Lin 2015]. We speculated that miR-29 expression levels in the ischemic region varied according to the detection time points after MI, so it is possible to detect miR-29 expression levels in the ischemic region at different time points after MI.

The most valuable findings from our study were that t-AUCB reversed miR-29 expression levels in the ischemic region after MI in mice dose-dependently. In the present study, we used 0.01 mg/L, 0.1 mg/L, and 1 mg/L t-AUCB, which all could downregulate miR-29 expression levels in...
the ischemic region of the myocardium at 24 h after MI in mice, and the differences were statistically significant. Previously, our group found that the myocardium infarct size was reduced markedly in MI mice treated with t-AUCB [Gui 2017; Gui 2018]. It is clear that t-AUCB acts on miR-29 and plays a role in anti-myocardial ischemia by regulating miR-29 expression levels.

Formerly, our study group did some electrophysiological experiments that were crucial to demonstrate the anti-arrhythmic effect of t-AUCB [Liu 2017; Gui 2017]. Consistently, our previous in vitro whole-cell patch-clamp recording demonstrated that the current density of IK1 (inward rectifier K+ current) was significantly reduced in miR-1 overexpression model of neonatal cardiac myocytes and t-AUCB could restore the IK1 current [Liu 2017]. Also, we performed surface electrocardiogram and simultaneous intracardiac electrograms from atria and ventricles from MI mice treated with or without t-AUCB. Compared with the MI group (70%), the incidence of ventricular tachycardia was decreased to 40%, and 38% in MI mice orally treated with 1 mg/L and 5 mg/L t-AUCB (all P < .05), respectively, revealing that sEHi could reduce the incidence of ventricular arrhythmias in MI mice [Gui 2017].

We found significantly decreased KCNJ12 mRNA and protein expression levels in the ischemic region after MI, and t-AUCB increased the KCNJ12 mRNA and protein expression levels dose-dependently. KCNJ12 is an ATP-sensitive inward rectifier potassium channel and encodes Kir2.2, which is involved in the formation of IK1 in the heart [Obukhov 2016]. The decreased function of Kir2.2 leads to the occurrence of electrical remodeling and the reduction of repolarization current at the end of an action potential, resulting in prolonged QT interval and action potential duration, which dramatically increase the risk of arrhythmias [Domenighetti 2007; Zaritsky 2001]. Many studies have confirmed that IK1 participated in the occurrence of ischemic arrhythmia after MI [Thireau 2015; Zhai 2017; Alexandre 2015]. Delapril, an angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist, inhibited the occurrence of arrhythmia simply by restoring damaged ion currents such as IK1 [Thireau 2015]. Also, we have proven that t-AUCB inhibited the occurrence of ventricular arrhythmias in mice with MI by restoring damaged IK1 [Liu 2017]. In the preliminary stage, we used a miRNA target prediction program and determined that KCNJ12 was a target gene of miR-29, and confirmed that upregulating miR-29 would downregulate KCNJ12. T-AUCB dose-dependently downregulated miR-29 and upregulated KCNJ12 in this study, which indicated that t-AUCB might regulate the expression of inward rectifier potassium channel proteins and affect the inward rectifier potassium current, and eventually play a role in anti-ischemic arrhythmias. Further experiments using miR-29 agomir or antagonir are required to verify the negative regulatory relationship between miR-29 and KCNJ12. Meanwhile, we will perform experimental studies in vitro.

We found significantly decreased KCNIP2 mRNA and protein expression levels in the ischemic region after MI and that t-AUCB increased the KCNIP2 mRNA and protein expression levels dose-dependently. The KCNIP2 gene encodes a member of the voltage-gated potassium (Kv) KCNIP2 family. Kv4.2 and Kv4.3 are the main components of transient outward potassium current (Ito), which is a potassium ion current on the myocardial cell membrane and mainly participates in the early repolarization of action potential [Deschênes 2002]; Ito abnormality is closely related to ischemic arrhythmias [Lundby 2010; Liu 2016]. Myers et al found that decreased Kv4.2 expression levels significantly attenuated Ito and greatly prolonged action potential duration [Myers 2015]. Accordingly, we speculated that t-AUCB might also play a role in anti-ischemic arrhythmias by recovering Ito via up-regulation of the KCNIP2 gene. In the preliminary experiment, we observed that KCNIP2 was also miR-29 target gene via miRNA target prediction program and proved initially the negative regulatory relationship between miR-29 and KCNIP2. T-AUCB dose-dependently reversed the above results, which shows that KCNIP2 might be involved in t-AUCB regulation of ischemic arrhythmias.

The present study confirms that t-AUCB regulates the expression of the potassium ion channel-related proteins KCNJ12 and KCNIP2 to some degree. Nonetheless, we do not know how or through which signaling pathway t-AUCB regulates miR-29 in the early phase of MI. There are few articles on miR-29 regulation: some studies reported that the PI3K/Akt (phosphatidylinositol 3-kinase/ protein kinase B, PI3K/Akt) signaling pathway participated in p eroxisome proliferator–activated receptor-gamma (PPARγ) downregulation of miR-29 expression levels in the ischemic myocardium [Ye 2010; Yasuda 2009]. Meanwhile, other studies have shown that EETs were natural ligands and endogenous agonists of PPARγ and activation of PPARγ signaling played a crucial role in EET-mediated protection in cardiomyocytes [Samokhvalov 2014]. Accordingly, we speculated that sEHi probably regulated miR-29 through the PI3K/Akt signaling pathway. Moreover, it has been indicated that other regulatory factors such as serum response factor (SRF) and myocyte enhancer factor 2 (MEF-2) were involved in EET regulation of miRNAs. These regulatory factors and cell signal transduction pathways might connect and interact with each other and function by forming a regulatory network that regulates the downstream effector proteins [Zhang 2011; Wei 2017], although the specific mechanism remains unknown, and clearly further research is needed to clarify potential links. Additionally, many studies have found that miRNA could regulate several ion currents by regulating the expression of various ion channel proteins associated with arrhythmias, and thereby play a role in mediating arrhythmias [Gui 2018; Liu 2017; Myers 2015; Zhou 2018]. miR-29 is one of the etiological factors of ischemic arrhythmia [Dawson 2013; Boštjančič 2014], and plays an important role in the anti-arrhythmia effect of sEHi. Our study indicated that miR-29 itself may serve as a novel target for the prevention and treatment of ischemic arrhythmia, which is of translational potential in future clinical studies.
**Study Limitations**

We didn’t include the electrocardiograph or other arrhythmia-related data, which is of paramount importance to demonstrate exactly which effects t-AUCB have on the genesis of ventricular arrhythmias in the very acute (within 24 hr) period; whereas, the anti-arrhythmia efficacy of t-AUCB has been proven in our previous work [Gui 2018]. Additionally, it cannot be excluded that sEHi had a protective effect and reduced infarct size and effects on miR-29 and ion channels could be secondary to this effect. Furthermore, we didn’t compare the effects of t-AUCB with other sEHi to show if this is a class effect of this group of agents or possibly results from some off-target effect and is specific for t-AUCB only.

**Conclusion**

MiR-29 expression levels are significantly increased in the infarct border zone and the mRNA and protein expression levels of its target genes KCNJ12 and KCNIP2 are significantly decreased. At 24 h after MI in mice, t-AUCB dose-dependently reverses these changes. However, further study is required to elucidate the mechanism of this effect.

**REFERENCES**


Obukhov AG, Scherer D, Seyler C, et al. 2016. Inhibition of cardiac Kir current (I(Kr)) by protein kinase C critically depends on Kir2.2. Plos One 11.


Zaritsky JJ, Redell JB, Tempel BL, et al. 2001. The consequences of disrupting cardiac inwardly rectifying K(+) current (I(K1)) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. J Physiol (Lond) 253:697-710.